Market capitalization | $18.59b |
Enterprise Value | $17.06b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.51 |
P/S ratio (TTM) P/S ratio | 6.00 |
P/B ratio (TTM) P/B ratio | 6.03 |
Revenue growth (TTM) Revenue growth | 71.01% |
Revenue (TTM) Revenue | $3.10b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
30 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
30 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 3,097 3,097 |
71%
71%
|
|
Gross Profit | 2,540 2,540 |
78%
78%
|
|
EBITDA | -791 -791 |
48%
48%
|
EBIT (Operating Income) EBIT | -886 -886 |
45%
45%
|
Net Profit | -524 -524 |
70%
70%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
Head office | Cayman Islands |
CEO | John Oyler |
Employees | 10,000 |
Founded | 2010 |
Website | www.beigene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.